Engerix-B market forecast points to faster growth in Asia-Pacific

The Business Research Company says the global Engerix-B vaccine market will expand through 2035 as hepatitis B remains widespread, adult vaccination programs widen and healthcare spending rises. North America led the market in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - Engerix-B is a hepatitis B vaccine used to prevent a serious liver infection that can lead to chronic disease, liver damage and liver cancer. - Market growth reflects broader public health priorities, including preventive immunization, workforce protection and higher vaccine coverage in high-risk groups. - The report points to demand growth from adult vaccination, booster dosing and expansion in emerging economies.

What happened: - The Business Research Company released its Engerix-B Global Market Report 2026, covering market size, trends and forecasts for 2026-2035. - The report says North America held the largest share of the Engerix-B market in 2025. - The report says Asia-Pacific is expected to be the fastest-growing region. - The report includes an option to download a free sample of the Engerix-B market report. - The report also offers the full Engerix-B market report.

The details: - Engerix-B contains hepatitis B surface antigen, or HBsAg, which triggers an immune response without causing infection. - The vaccine is designed to help the body build immunity against hepatitis B virus, or HBV. - The report ties past market growth to widespread hepatitis B prevalence, adoption of recombinant vaccine technology, government immunization campaigns, public health awareness and childhood vaccination drives. - The report links future growth to broader adult vaccination programs, stronger healthcare worker safety efforts, higher vaccination rates in emerging economies and more public health funding. - The report highlights universal rollout of hepatitis B vaccination, preventive immunization initiatives, adult and booster dose demand, stronger vaccination policy and improved coverage in high-risk populations as key trends. - Rising HBV infection rates are a core market driver because the virus can spread through unprotected sex, blood-to-blood contact, lack of vaccination and weakened immune systems. - The World Health Organization in April 2024 set a global objective of 80% treatment coverage for people with chronic hepatitis B and C by 2030. - Rising healthcare spending is also supporting vaccine access by funding immunization programs, infrastructure and affordability. - The UK Office for National Statistics said total healthcare expenditure rose 5.6% nominally between 2022 and 2023, compared with 0.9% growth in the prior year. - The report says international travel and migration are adding demand because travelers and migrants can face higher exposure risk in regions where hepatitis B is more common. - The UK Office for National Statistics said visits to the UK reached 38.0 million in 2023, up 6.7 million from 2022, while outbound trips by UK residents increased to 86.2 million from 71.0 million. - The report says 2026 editions now include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics and updated technology and trend analysis.

Between the lines: - The report frames Engerix-B demand as part of a larger shift toward prevention rather than treatment after infection. - Higher mobility, more public health funding and broader vaccination policy all point to wider routine use rather than only crisis-driven uptake. - The regional outlook suggests mature markets still dominate revenue, but faster growth is shifting toward countries investing more in immunization infrastructure.

What's next: - The market will likely track expansion in adult vaccination campaigns, booster programs and public sector immunization funding. - Asia-Pacific growth will depend on how quickly governments and health systems scale vaccine access and coverage. - The report’s forecast window runs through 2035, giving investors and health planners a long-range view of demand patterns.

The bottom line: - Engerix-B is positioned to benefit from a sustained global push on hepatitis B prevention, with growth driven by disease burden, higher health spending and widening vaccination programs.